Skip to content

    Hikal Limited

    CDMO maker of APIs, intermediates and crop-protection chemicals for global pharma and agrochem innovators.

    Healthcare
    Healthcare
    View HIKAL earnings calls
    ₹204.77
    +6.12% from avg

    Overview

    Price

    ₹204.77

    Market Cap

    ₹2.7k Cr

    Sector

    Healthcare

    Healthcare

    Rank

    5

    Performance

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly

    Balance Sheet

    Balance Sheet

    ₹ Cr · Annual
    Line itemFY20FY21FY22FY23FY24FY25FY26FY26
    LiabilitiesEquity Capital2525252525252525
    Reserves7929091.0k1.1k1.2k1.2k1.2k1.2k
    Borrowings646610675748818765683684
    Other Liabilities306370470504482502472483
    Total Liabilities1.8k1.9k2.2k2.4k2.5k2.5k2.3k2.4k
    AssetsFixed Assets7357138799481.1k1.4k1.3k1.3k
    CWIP16125429541241412113494
    Investments111155101010
    Other Assets8719461.0k1.0k9971.0k865928
    Total Assets1.8k1.9k2.2k2.4k2.5k2.5k2.3k2.4k

    Cash Flow

    Cash Flow

    ₹ Cr · Annual
    Line itemFY19FY20FY21FY22FY23FY24FY25FY26
    ActivitiesCash from Operating186285229294315187280302
    Cash from Investing-125-164-156-284-292-174-136-145
    Cash from Financing-55-101-97-6-8-27-144-160
    SummaryCapital Expenditure
    Free Cash Flow57127712113-17144154
    FCF Margin

    Valuation

    Cyclical, with too little history

    This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.

    HIKAL · CYCLICAL_UNMODELABLE

    Learn to analyse Hikal Limited

    Guides on how to read this kind of business and the numbers that matter.